Kinetic Targeting of pegylated liposomal Doxorubicin: a new Approach to Reduce Toxicity during Chemotherapy (CARL-trial)
<p>Abstract</p> <p>Background</p> <p>The therapeutic success of chemotherapeutic agents is often limited by severe adverse effects. To reduce toxicity of these drugs, nanoscale particle-based drug delivery systems (DDS) are used. DDS accumulate to some extent in tumor t...
Main Authors: | Jansen Martin, Hasenburg Annette, Rautenberg Beate, Zschiedrich Stefan, Groh Ursula, Siebers Jan W, Schmah Oliver, Eckes Jürgen, Hug Martin J, Winkler Karl, Pütz Gerhard |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2011-08-01
|
Series: | BMC Cancer |
Online Access: | http://www.biomedcentral.com/1471-2407/11/337 |
Similar Items
-
Pegylated liposomal doxorubicin in ovarian cancer
by: Robert Strother, et al.
Published: (2009-08-01) -
PEGylated Liposomal Doxorubicin Rechallenge following Doxorubicin-induced Pancreatitis
by: Luke Ardolino, et al.
Published: (2020-12-01) -
A tale of the two PEGylated liposomal doxorubicins
by: Chou HH, et al.
Published: (2015-07-01) -
Pegylated liposomal doxorubicin in the management of ovarian cancer
by: Gabriella Ferrandina, et al.
Published: (2010-09-01) -
Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
by: Zhen Yuan, et al.
Published: (2021-01-01)